Dabrafenib and trametinib for BRAF V600 cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Ear, nose & throat, Heart & circulation, Hormones & metabolism, Immune system & allergy, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a BRAF V600 mutation (a specific gene change) found by a genetic test.
- You must be at least 1 year old and weigh at least 8 kg (about 18 pounds).
- If you can become pregnant, you need a negative pregnancy test before starting and must use a non-hormonal birth control method (like an IUD or abstinence) during and for 16 weeks after treatment.
- If you are a man with a partner who could become pregnant, you must use a condom with spermicide or practice abstinence during and for 16 weeks after treatment.
- You must be willing to have a new tumor biopsy (small sample) and give blood samples for research.
- You cannot have certain common cancers that already have approved treatments (like adult colorectal cancer, melanoma, lung cancer, or certain brain tumors in children).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
This trial tests a combination of targeted therapy (dabrafenib or trametinib) with chemotherapy (clofarabine) for children with Langerhans cell histiocytosis (LCH) that is high-risk, has come back, or is not responding to other treatments. The goal is to see if this combination can help control the disease.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This trial tests a new drug (XP-102) alone or with another drug (trametinib) for people with advanced cancers that have a BRAF V600 mutation. The goal is to see if the treatment can help shrink or control the cancer.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Hear when a new Lymphoproliferative Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.